Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Updated Nov 13, 2026

Solicitation from the Defense Health Agency (DHA), for work in San Antonio, Texas. Due Dec 7, 2026, 12:00 PM (UTC-6), 24 days left.

Bid documents (7)

• FAR -Certificate 645 KB
• PandT Meeting Reporting 190 KB
• NDC Price List FAQ Class Review 227 KB
• PL - Ophthalmic - Dry Eye 44 KB
• PL - Testosterone Replacement Therapy - Orals 45 KB
• Request for Quotations 925 KB
• Http://health.mil/PandT

Paid members download every document from this page, or buy this bid alone.

Federal prevailing wage rates for this place: Texas Davis-Bacon and SCA wage determinations.

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).

Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision.

This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101.

Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.

Contracting contact

• Stephanie Erpelding · [email protected]
• Julianne Canaley · [email protected]

As published on the official notice. Ask questions in writing and before any questions deadline the notice sets.

Is your business small enough?

For NAICS 325412, a business counts as small if it has no more than 1,300 employees (SBA size standard). This notice is not set aside, but the size decides your small business status on it. SBA table, current as of Oct 15, 2026.

Pharmaceutical Preparation Manufacturing contracts right now

There are 26 open government contract opportunities in this trade (NAICS 325412), 11 posted in the last 7 days; 12% are set aside for small businesses. The agencies buying the most are Department of Veterans Affairs, Defense Logistics Agency and Defense Health Agency (DHA). Most of the work with a stated place is in Pennsylvania, Texas and Alabama. A notice in this trade gives a median of 23 days from posting to deadline; this one gives 25 days.

All open pharmaceutical preparation manufacturing contracts

Recent awards in this trade

• Denali Therapeutics Inc. $600,000 · Department of Veterans Affairs · Nov 4, 2026
• Novartis Pharmaceuticals Corporation $769,497 · Department of Veterans Affairs · Oct 29, 2026
• Nuclear Diagnostic Products Of Philadelphia, Inc $1.2 million · Department of Veterans Affairs · Oct 29, 2026
• Alembic Therapeutics LLC $475,000 · Department of Veterans Affairs · Oct 26, 2026
• Avkare LLC $1.6 million · Department of Veterans Affairs · Oct 23, 2026

From the award notices agencies publish.

Similar open pharmaceutical preparation manufacturing bids